PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer

Abstract

This study proposed to investigate the relationship of PIK3CA somatic mutations, the most common activating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy (NCT).Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN, EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93 BC patients treated with epirubicin plus docetaxel NCT.PIK3CA mutations were found in 30 patients (32.3%), in which the point mutations of E542K, E545K, H1047L and H1047R were 4.3, 9.7, 4.3 and 14.0% respectively. The PIK3CA mutations were significantly associated with patients' clinical response; 27 of 30 PIK3CA mutated patients had either a partial or complete response (p=0.002). Multivariate analysis further confirmed that, after adjustments for age, disease stages and NCT cycles, PIK3CA was associated with clinical response (Odds Ration 0.126, 95% CI [0.029, 0.691]). However, there was no significant difference between PIK3CA mutations in pathological complete response (pCR, 7/92) and non-pCR group. Furthermore, no EGFR, KRAS and BRAF mutations were detected in any of the 93 samples.Our data for the first time suggested that PIK3CA mutation status may be a predictor for better understanding clinical response to the combination of epirubicin and docetaxel NCT in patients with BC.

PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta‐analysis

“…As shown in Table , 20 studies including 4392 patients were included in our meta‐analysis . Overall, PIK3CA mutation incidence in our meta‐analysis was 22.4% (range 7.7–39.0%).…”

“…pCR was 28% for PIK3CA MT and 38% for PIK3CA WT. Seven studies were conducted in the United States, nine in Europe, and four in Asia . Two studies included objective response rate, while the others reported pCR as the endpoint in WT versus MT PIK3CA tumors.…”

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function

“…However, PTEN gene expression was categorized only as up- or downregulated in this microarray analysis, with no further quantification [30]. Another study found PTEN gene expression to be significantly higher in 93 human breast cancer samples as compared to healthy breast tissue; however, the potential impact on survival was not assessed [31]. …”

Early Indian Summer Monsoon Onset Driven by Low Soil Moisture in the Iranian Desert

“…As the time at which the Indian summer monsoon (ISM) starts can directly affect agriculture, the economy, and society in general, it is important to understand the onset of the summer monsoon (Moon & Ha, 2017;Ueda et al, 2015;Webster et al, 1998;Zhang et al, 2014). The social impact of not only the monsoon but also the start date is severe, especially in populated regions (Moon & Ha, 2017;Turner & Annamalai, 2012;Webster et al, 1998;Zhang et al, 2014). Note that the relationship between the monsoon rainfall rate and early monsoon onset is not linear (Figure 1b).…”